Greer Capital Advisors

ViroXis Corporation is a bio-pharmaceutical company based in San Antonio, Texas, that specializes in the development and commercialization of innovative botanical pharmaceuticals derived from East Indian sandalwood oil. Founded in 2006, the company has created a botanical ointment formulated from Santalum album oil, which is used to treat human papillomavirus (HPV) infections of the skin in both children and adults. Additionally, ViroXis is developing an EISO cream aimed at addressing other HPV infections and skin pox. The company has established strategic partnerships with TFS Corporation Ltd. and DPT Laboratories, Inc., enhancing its capabilities in the biopharmaceutical sector.

PNP Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. Established in 2000 and headquartered in Birmingham, Alabama, the company utilizes a proprietary platform based on the selective expression of E. coli purine nucleoside phosphorylase. This patented enzyme facilitates the activation of various nucleoside prodrugs, leading to the production of active metabolites that exhibit significant anti-tumor activity. PNP Therapeutics aims to enhance cancer treatment by directly targeting tumor cells within a controlled environment, thereby improving patient outcomes.

TransMolecular, Inc. is a neuroscience biotechnology company dedicated to discovering, developing, and commercializing innovative drugs aimed at diagnosing and treating central nervous system diseases, particularly focusing on cancer and pain management. Founded in July 1996 and based in Birmingham, Alabama, the company has established robust technology platforms that enhance its product discovery and development pipeline. TransMolecular has received significant funding through private placements and Small Business Incentive Research grants from the National Institutes of Health, totaling $1 million for its cancer and pain programs. The company holds over 25 patents and has exclusive licensing agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its specialized technologies. Its management team, boasting more than 75 years of combined experience in healthcare, pharmaceutical development, and research, is committed to advancing safe and effective therapeutic solutions for patients with limited treatment options.